Increased p16 and p53 protein expression predicts poor prognosis in mucosal melanoma.

Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer (1998) 6.22

Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer (2006) 3.23

Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol (2003) 1.93

The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol (2000) 1.76

The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol (2001) 1.73

Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med (2011) 1.57

In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res (2001) 1.51

Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res (2011) 1.47

Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer (1998) 1.28

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res (2004) 1.21

Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol (2003) 1.20

Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res (1999) 1.19

The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res (2013) 1.08

Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res (2003) 1.02

Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer (1997) 1.02

PIG3: a novel link between oxidative stress and DNA damage response in cancer. Cancer Lett (2011) 1.00

The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol (2007) 1.00

Combined P16 and human papillomavirus testing predicts head and neck cancer survival. Int J Cancer (2014) 0.98

Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer (2010) 0.97

Interaction of p53 with tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production. Antioxid Redox Signal (2011) 0.97

Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer (2006) 0.95

Role of MnSOD and p66shc in mitochondrial response to p53. Antioxid Redox Signal (2011) 0.95

Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene (2000) 0.92

Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther (2001) 0.92

Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene (2002) 0.91

Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer. Br J Cancer (2012) 0.90

Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Res Treat (2009) 0.89

Clinicopathological findings of primary esophageal malignant melanoma: report of six cases and review of literature. Int J Clin Exp Pathol (2014) 0.89

Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer (1997) 0.88

Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. J Neurooncol (2006) 0.87

p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol (1995) 0.85

Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck. Head Neck Pathol (2011) 0.84

High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol (2014) 0.84

Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol (2015) 0.83

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chin Clin Oncol (2015) 0.78

Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey. APMIS (2016) 0.77

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget (2016) 0.75

Inhibition of Lon blocks cell proliferation, enhances chemosensitivity by promoting apoptosis and decreases cellular bioenergetics of bladder cancer: potential roles of Lon as a prognostic marker and therapeutic target in baldder cancer. Oncotarget (2014) 0.83

Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget (2016) 0.77

Increased p16 and p53 protein expression predicts poor prognosis in mucosal melanoma. Oncotarget (2017) 0.75